1. Bruker Corporation (NASDAQ: BRKR)
Q4 and FY 2013 Earnings Presentation
Frank Laukien, President & CEO
Charles Wagner, EVP & CFO
February 18, 2014
Joshua Young, VP, Investor Relations
Innovation with Integrity

2. Bruker Corporation
Safe Harbor & Reg. G Statement
Any statements contained in this presentation that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained herein are based on current expectations, but are subject to
risks and uncertainties that could cause actual results to differ materially from those projected, including,
but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy
and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the
future, changing technologies, product development and market acceptance of our products, the cost and
pricing of our products, manufacturing, competition, dependence on collaborative partners and key
suppliers, capital spending and government funding policies, changes in governmental regulations,
realization of anticipated benefits from economic stimulus programs, intellectual property rights,
litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time
in our filings with the Securities and Exchange Commission. These and other factors are identified and
described in more detail in our filings with the SEC, including, without limitation, our annual report on
Form 10-K for the year ended December 31, 2012, our most recent quarterly reports on Form 10-Q and
our current reports on Form 8-K. We will also be referencing non-GAAP financial measures in this
presentation. A reconciliation of non-GAAP to GAAP results is available in our earnings press release and
in this presentation.
© Bruker Corporation
2

3. Q4 & FY 2013 Business Update
© Bruker Corporation
3

4. Strong finish to 2013 driven by European academic
markets, solid BioSpin performance
Q4 2013 Performance
 Organic revenue growth of 6.2% y-o-y
1. Double-digit revenue growth in BioSpin
driven by NMR demand in Europe; PreClinical Imaging division rebounds
Q4 Financials
+7%
Revenues [$ m]
552
517
2. CALID revenues grow mid-single digits
3. BMAT revenues decline mid-teens due to
weakness in industrial markets,
particularly in Asia
 Operating leverage drives 60 bps non-GAAP
operating margin expansion
Q4 12
Operating Margin*
+60 bps
* Non-GAAP
 11% non-GAAP EPS growth in Q4 2013
compared to Q4 2012
Q4 2012
 Free cash flow of $122M in Q4 2013
Q4 2013
© Bruker Corporation
Q4 13
14.1%
14.7%
4

5. Good revenue growth in life sciences, offset by
industrial weakness; FX headwinds lower profitability
FY 2013 Performance
 Organic revenue growth of 3.2%
1. BioSpin delivers high-single digit
revenue growth; double-digit growth in
bookings driven by high-field NMR
FY2013 Performance
+3%
Revenues [$ bn]
1.79
1.84
FY 12
FY 13
2. CALID grows mid-single digits driven by
strong performance of Optics Division
3. BMAT declines high-single digits
 Non-GAAP operating margins decline by ~100
bps; changes in FX lowered operating
margins by more than 100 bps
Operating Margin*
* Non-GAAP
 Non-GAAP EPS of $0.77 compared to $0.83 in
FY 2012
YTD 12
 Free cash flow increases by $34M y-o-y to
$95M
YTD 13
© Bruker Corporation
-100 bps
12.2%
11.2%
5

6. GROUP OVERVIEW:
FY 2013 Performance
Bruker BioSpin Group
 Strong growth in both revenue and new order bookings
 Performance driven by robust academic demand in Europe, Japan
 Pre-Clinical Imaging Division rebounds and posts good growth for
the year as more large MRI installations are completed in Q4
 Settlement with Perkin Elmer in Q1-14 in optical imaging
 Outsourcing & divestiture milestones achieved in 2013
Bruker CALID* Group
 Optics Division growth from new products Lumos and Tango
 Life Science & Clinical Division’s growth driven by MALDI Biotyper
(MBT) and FTMS; FDA clears first MBT claim in Q4-13
 CAM division: narrowing strategic focus and reducing costs
 Restructuring milestones reached late in Q4-13
 Q1-14: Combining commercial management of CAM and
LSC to optimize market coverage and improve efficiency
* Chemical, Applied Markets, Life Science, In-Vitro Diagnostics, Detection
© Bruker Corporation
6

7. GROUP OVERVIEW:
FY 2013 Performance
Bruker MAT Group
 Substantial weakness in industrial markets and Asia, particularly in
semiconductor, data storage and microelectronics industry
 New order bookings stabilized and grew in 2nd half of 2013
 Bruker Nano Surfaces Division seeing good demand for AFM Fast
Scan, and new Fluorescence Microscopy products
 Good execution on controlling costs and mitigating the effect s of
revenue decline on profitability
BEST Segment
 Revenue growth of 8%; non-GAAP operating margin of 8.6%
includes $5.7 million in Rosatom license revenues
• Ex-Rosatom, FY13 revenue growth was 18% y-o-y
• Ex-Rosatom, FY13 non-GAAP operating margin was 4.9%
 Solid improvement in profitability (ex-Rosatom), additional actions
taken should benefit FY14 performance
© Bruker Corporation
7

8. Transformation: We have made significant progress in
2013 and will continue in 2014-2015
Leadership/Organization
• New CFO and three new
Group presidents
• 10 BSI operating divisions
organized into 3 groups
• Incentive systems
changed to have more
emphasis on profit and cash
flow
Processes/Systems
• Transitioning to global
business model, from
country/legal entity model
• Launched restructuring
initiatives in all businesses
• Implementing new
financial consolidation
system
• Internal lean initiatives
combined with outsourcing
and selected divestitures
• Implementing and
harmonizing ERP systems
• Reduced HC by ~300 via
previously announced
actions
• Continued CRM roll-outs
© Bruker Corporation
Restructuring/Productivity
• Effectively managing OPEX
8

9. Q4 and FY 2013 Financial Update
© Bruker Corporation
9

10. NON-GAAP FINANCIAL PERFORMANCE:
Q4 2013 Overview
[$ m, except EPS]
Δ
Operating Income
Margin (%)
EPS
Free Cash Flow
[$ m]
Net Cash/(Debt)
Working capital (WC)*
WC-to-revenue ratio
Q4 2012
552.1
517.3
7%
81.3
73.0
11%
14.7%
14.1%
0.31
Revenues
Q4 2013
0.28
11%
122.4
67.9
54.5M
Dec 31,2013
Dec 31,2012
Δ
83.7
(26.6)
415%
822.6
831.2
-1%
0.45
0.46
-0.017
COMMENTS
 Margin expansion driven by
lower operating expenses
 FY13 EPS benefits from
lower tax rate
 Improving cash flow
reflects higher profitability
and efforts to improve
working capital efficiency
* WC = (Accounts Receivable +
Inventory – Accounts Payable)
© Bruker Corporation
10

11. Q4 2013 revenue bridge
Q4 2013 Revenue Growth for Bruker Corp.
Organic
6.2%
Acquisitions &
Divestitures
Currency
0.4%
0.1%
Total
6.7%
0.5
 Positive currency impact
primarily the result of a
strengthening Euro
2.0
552.1
517.3
Q4 2012
 Solid organic revenue
growth to exit 2013
 First quarter of BMAT
revenues from Prairie
acquisition
Q4 2013 Revenue bridge [$ m]
32.3
Q4 2013 DRIVERS
Organic
© Bruker Corporation
Currency
Acquisition
Q4 2013
11

12. Q4 2013 Non-GAAP Results
[$ m]
Δ
Q4 2013
Q4 2012
Total Revenues
552.1
517.3
7%
Gross Profit
248.3
246.4
1%
45.0%
47.6%
-117.9
-123.1
21.4%
23.8%
-49.1
-50.3
(% of revenues)
8.9%
9.7%
Operating Income
81.3
73.0
14.7%
14.1%
52.2
46.7
12%
EPS
$0.31
$0.28
11%
Shares Outstanding
169.0
167.7
COMMENTS
NM
Margin (% of sales)
SG&A
(% of revenues)
R&D
(% of revenues)
Net Income*
-4%
-2%
11%
 BioSpin and CALID drive
higher revenues
 Gross margins lowered
by currency and mix
 Solid control of
discretionary spending
drives lower Opex
 Lower year-over-year tax
rate driven by
jurisdictional mix
Sum of items may not total due to rounding
* Attributable to Bruker
© Bruker Corporation
12

13. Q4 2013 Reconciliation of GAAP to
Non-GAAP Results
[$ m]
Q4 2013
Q4 2012
61.0
39.2
11.7
0.5
Acquisition Related Costs
2.3
0.2
Purchased Intangible Amortization
5.4
5.8
Other Costs
0.9
27.3
20.3
33.8
81.3
73.0
Non-GAAP Net Interest Income (Expense) & Other
-7.2
-4.7
Non GAAP Profit Before Tax
74.1
68.3
-21.2
-21.1
28.6%
30.9%
-0.7
-0.5
52.2
46.7
$0.31
$0.28
GAAP Operating Income
Restructuring Costs
TOTAL
Non-GAAP Operating Income
Taxes
Non-GAAP Tax Rate
Minority Interest
Non-GAAP Net Income**
Non-GAAP EPS
** Attributable to Bruker
© Bruker Corporation
Sum of items may not total due to rounding
13

14. FY 2013 Non-GAAP Results
[$ m]
Total Revenues
FY 2013
FY 2012
Δ
1,839.4
1,791.4
3%
832.5
851.3
-2%
45.3%
47.5%
-436.5
-437.0
23.7%
24.4%
-190.5
-195.3
(% of revenues)
10.4%
10.9%
Operating Income
205.5
219.0
(% of revenues)
11.2%
12.2%
Net Income*
129.3
138.3
-7%
EPS
$0.77
$0.83
-7%
Shares Outstanding
168.5
167.4
NM
Gross Profit
Margin (% of sales)
SG&A
(% of revenues)
R&D
NM
-2%
-6%
Sum of items may not total due to rounding
* Attributable to Bruker
© Bruker Corporation
14

15. FY 2013 Reconciliation of GAAP to
Non-GAAP Results
[$ m]
FY 2013
FY 2012
GAAP Operating Income
148.2
156.0
25.3
0.9
4.5
3.1
20.7
22.0
6.8
37.0
57.3
63.0
Non-GAAP Operating Income
205.5
219.0
Non-GAAP Net Interest Income (Expense) & Other
-26.0*
-19.9*
Non GAAP Profit Before Tax
179.5
199.1
Taxes
-48.5
-60.1
27.0%
30.2%
-1.7
-0.7
Non-GAAP Net Income**
129.3
138.3
Non-GAAP EPS
$0.77
$0.83
Restructuring Costs
Acquisition Related Costs
Purchased Intangible Amortization
Other Costs
TOTAL
Non-GAAP Tax Rate
Minority Interest
*Excludes $2.4 and $2.2 million of gains for 2013 and 2012
**Attributable to Bruker
© Bruker Corporation
Sum of items may not total due to rounding
15

16. Balance sheet
[$ m]
Total Assets
Dec 31, 2013
Dec 31, 2012
Δ
1,988.3
1,856.4
7%
Equity
850.2
709.7
20%
Cash & Cash Equivalents
438.7
310.6
41%
Inventory
589.8
611.5
-4%
Intangible & Other Assets
256.9
263.1
-2%
Financial Debt
355.0
337.2
5%
83.7
(26.6)
415%
Net Cash/(Debt)
© Bruker Corporation
16

17. FY 2013 Cash Flow Statement
[$ m]
Δ
FY 2013
FY 2012
Net Income
81.8
78.2
3.6
Depreciation & amortization
61.3
59.1
2.2
Changes in working capital
-10.6
-52.3
41.7
12.5
48.1
-35.6
145.0
133.1
11.9
Capital expenditures
-50.3
-72.8
22.5
Free cash flow
94.7
60.3
34.4
Other
Operating cash flow
© Bruker Corporation
17

18. 2014 Guidance
© Bruker Corporation
18

19. FY 2014 Guidance
Bruker FY 2014 Guidance
Revenue Growth (reported)
Restructuring Costs
Non-GAAP Tax Rate
Non-GAAP EPS Growth
© Bruker Corporation
ASSUMPTIONS
3% to 4%
~$15-$20M
~29%-30%
10% to 14%
 Similar level of top-line
growth from all three
Groups: BioSpin, CALID,
and BMAT
 Less than $50M of capex
spending
 After strong Q4-13, Q1-14
financial performance
expected to be similar to
Q1-13 performance
 Currency assumptions
against US dollar:
Yen/USD: 104
EUR/USD: 1.36
19

20. Appendix
© Bruker Corporation
20

21. Q4 2013 GAAP Results
Δ
[$ m]
Q4 2013
Q4 2012
Total Revenues
552.1
517.3
7%
Gross Profit
235.9
241.7
-2%
42.7%
46.7%
-118.3
-124.0
21.4%
24.0%
-49.1
-50.3
(% of revenues)
8.9%
9.7%
Operating Income
61.0
39.2
11.0%
7.6%
35.2
12.8
175%
EPS
$0.21
$0.08
163%
Shares Outstanding
169.0
167.7
NM
Margin (% of sales)
SG&A
(% of revenues)
R&D
(% of revenues)
Net Income*
-5%
-2%
56%
Sum of items may not total due to rounding
* Attributable to Bruker
© Bruker Corporation
21

22. FY 2013 GAAP Results
[$ m]
Total Revenues
FY 2013
FY 2012
Δ
1,839.4
1,791.4
3%
805.2
829.4
-3%
43.8%
46.3%
-437.9
-440.4
23.8%
24.6%
-190.5
-195.3
(% of revenues)
10.4%
10.9%
Operating Income
148.2
156.0
(% of revenues)
8.1%
8.7%
80.1
77.5
3%
EPS
$0.48
$0.46
4%
Shares Outstanding
168.5
167.4
NM
Gross Profit
Margin (% of sales)
SG&A
(% of revenues)
R&D
Net Income*
-1%
-2%
-5%
Sum of items may not total due to rounding
* Attributable to Bruker
© Bruker Corporation
22

23. FY 2013 revenue bridge
FY 2013 Revenues for Bruker Corp.
Organic
Currency
Acquisitions &
Divestitures
Total
3.2%
-0.3%
-0.2%
2.7%
YTD 2013 Revenue bridge [$ m]
57.1
-5.3
-3.8
1,791.4
FY 2012
© Bruker Corporation
1,839.4
Organic
Currency
Acquisition
FY 2013
23

24. Q4 2013 Cash Flow Statement
[$ m]
Q4 2013
Q4 2012
Δ
Net Income
35.9
13.3
22.6
Depreciation & amortization
15.9
16.6
-0.7
Changes in working capital*
22.0
-9.5
31.5
Other
57.6
70.5
-12.9
131.4
90.9
40.5
-9.0
-23.0
67.9
 Strong free cash flow
14.0
122.4
COMMENTS
54.5
Operating cash flow
Capital expenditures
Free cash flow
© Bruker Corporation
 Improvement in working
capital primarily result of
better management of
inventory
 Lower capex related to
the timing of projects,
and a concerted effort to
reduce spending
24

25. Q4 SEGMENT RESULTS:
BSI and BEST GAAP Performance
[$ m]
Δ
Q4 2013
Q4 2012
511.0
482.1
5.9%
9.2%
46.6
37.8
Organic Revenue Growth (%)
17.4%
16.5%
Corporate Eliminations & Other
-5.5
-2.6
552.1
517.3
7%
54.9
34.5
59%
Energy & Supercon Technologies (BEST)
2.8
-0.6
566%
Corporate Eliminations and Other
3.3
5.3
61.0
39.2
REVENUE
Scientific Instruments (BSI)
Organic Revenue Growth (%)
Energy & Supercon Technologies (BEST)
Total Revenue
6%
23%
OPERATING INCOME (LOSS)
Scientific Instruments (BSI)
Total Operating Income (Loss)
© Bruker Corporation
56%
25